Usefulness of Non TNF Usage in RA Patients

Usefulness of Non TNF Usage in Rheumatoid Arthritis Patients

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03784261

Enrollment

Registered

2018-12-21

Start date

2018-12-17

Completion date

2024-12-16

Last updated

2021-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Brief summary

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in rheumatoid arthritis patients: 1. Sarilumab treatment for 12 months 2. Tocilizmab treatment for 12 months 3. Abatacept treatment for 12 months

Interventions

DRUGDrug: Salirumab

To examine the effects of salirumab in RA patients

DRUGDrug: Tocilizmab

To examine the effects of tocilizmab in RA patients

DRUGDrug: Abatacept

To examine the effects of abatacept in RA patients

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

20 Years to 100 Years

Healthy volunteers

Inclusion criteria

・RA patients

Exclusion criteria

* Not RA patients * RA patients who are allergic to the drugs, refused to do this research, or who are pregnant

Design outcomes

Primary

Measure	Time frame	Description
Change from Baseline Values of DAS28-CRP	Baseline and 1 year	Assessment of efficacy in rheumatoid arthritis patients for 1 year treated by salirumab (N=30), tocilizumab (N=30), or abatacept (N=30).
Assessment of adverse event in rheumatoid arthritis patients for 1 year treated by salirumab (N=30), tocilizumab (N=30), or abatacept (N=30).	at 1 year	—

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026